Look back at pharma news to August 26

28 August 2016

By Barbara Obstoj-Cardwell. Editor

Bernstein analyst Tim Anderson and team wonder if Pfizer winning the bidding war for Medivation with its $14 billion offer ( announced last Monday) is “something to be proud of,” reported Barron’s magazine.

At first pass, paying $80+/share for a stock that was trading in the $30′s just a few months ago feels pricey. What Pfizer gains is Medivation’s cut of Xtandi, and a Phase III PARP inhibitor, talazoparib, that Medivation itself recently bought from BioMarin. Medivation's prostate cancer treatment Xtandi generates close to $2 billion in annual sales and is projected to earn $4.8 billion in annual sales by 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK